StockNow
Log in
U.S. Markets

Eli Lilly (LLY) spokesperson confirmed that it will allow other patients to apply for early access to retatrutide, Stat News reports

StockNow breaking-news AI analysis

Eli Lilly confirms expanded early access for retatrutide, its potent triple agonist for obesity. Phase 3 results show record-breaking efficacy, with FDA filing targeted for Q1 2027.

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

LLYGeopolitics

Pakistani sources say Pakistan PM Sharif and Army Chief Munir will visit Saudi Arabia tomorrow, Al Hadath reports

U.S. Economy

US ADP Employment Change (Jul) 44K vs. Exp. 70K (Prev. 98K)